JP2010522208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522208A5 JP2010522208A5 JP2009554753A JP2009554753A JP2010522208A5 JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5 JP 2009554753 A JP2009554753 A JP 2009554753A JP 2009554753 A JP2009554753 A JP 2009554753A JP 2010522208 A5 JP2010522208 A5 JP 2010522208A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- liquid formulation
- imc
- polysorbate
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012669 liquid formulation Substances 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 3
- 229950006647 cixutumumab Drugs 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000007979 citrate buffer Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91974407P | 2007-03-22 | 2007-03-22 | |
| PCT/US2008/057718 WO2008116103A2 (en) | 2007-03-22 | 2008-03-20 | Stable antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522208A JP2010522208A (ja) | 2010-07-01 |
| JP2010522208A5 true JP2010522208A5 (OSRAM) | 2011-04-28 |
Family
ID=39766776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554753A Pending JP2010522208A (ja) | 2007-03-22 | 2008-03-20 | 安定な抗体処方物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100260766A1 (OSRAM) |
| EP (1) | EP2136839A4 (OSRAM) |
| JP (1) | JP2010522208A (OSRAM) |
| KR (1) | KR20090113340A (OSRAM) |
| CN (1) | CN101668540A (OSRAM) |
| AU (1) | AU2008228823A1 (OSRAM) |
| BR (1) | BRPI0809112A2 (OSRAM) |
| CA (1) | CA2681743A1 (OSRAM) |
| CR (1) | CR11005A (OSRAM) |
| DO (1) | DOP2009000222A (OSRAM) |
| EA (1) | EA200970880A1 (OSRAM) |
| EC (1) | ECSP099642A (OSRAM) |
| IL (1) | IL200321A0 (OSRAM) |
| MX (1) | MX2009010179A (OSRAM) |
| TN (1) | TN2009000382A1 (OSRAM) |
| UA (1) | UA96473C2 (OSRAM) |
| WO (1) | WO2008116103A2 (OSRAM) |
| ZA (1) | ZA200905636B (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| TW200838559A (en) * | 2006-11-29 | 2008-10-01 | Imclone Systems Inc | Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| CN102272154A (zh) | 2008-10-29 | 2011-12-07 | 惠氏有限责任公司 | 单域抗原结合性分子的纯化方法 |
| CA2738243C (en) | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| BRPI0921845A2 (pt) * | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| MY150984A (en) | 2008-12-12 | 2014-03-31 | Boehringer Ingelheim Int | Anti-agf antibodies |
| TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| TWI621625B (zh) | 2010-09-17 | 2018-04-21 | 巴克斯歐塔公司 | 在弱酸性至中性ｐｈ中經由具有組胺酸的水性調配物穩定免疫球蛋白 |
| HUE044038T2 (hu) | 2010-11-05 | 2019-09-30 | Novartis Ag | Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| KR102091294B1 (ko) * | 2011-10-26 | 2020-04-16 | 암젠 인크 | Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법 |
| CN107880123A (zh) | 2011-10-28 | 2018-04-06 | 普罗典娜生物科学有限公司 | 识别α‑突触核蛋白的人源化抗体 |
| AU2013211874B2 (en) | 2012-01-27 | 2017-11-02 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| AR094821A1 (es) * | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| AR091902A1 (es) * | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| JP2016505601A (ja) | 2012-12-26 | 2016-02-25 | ウォックハート リミテッド | 医薬組成物 |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| NL1040254C2 (en) * | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| CA2944402A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| EP3256154B1 (en) * | 2015-02-09 | 2019-10-02 | UCB Biopharma SPRL | Pharmaceutical formulation comprising antibody |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| EP4516319A3 (en) * | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| JP6992262B2 (ja) * | 2016-03-31 | 2022-02-15 | 東ソー株式会社 | 変性抗体測定試薬の製造方法 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| CN112206320B (zh) * | 2019-07-12 | 2025-02-25 | 鲁南制药集团股份有限公司 | 一种cd47单克隆抗体冻干粉制剂及其制备工艺 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) * | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| EP0940468A1 (en) * | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| IL155002A0 (en) * | 2000-10-12 | 2003-10-31 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
| DK2270052T3 (en) * | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| MXPA04007924A (es) * | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| PL378812A1 (pl) * | 2003-02-13 | 2006-05-29 | Pfizer Products Inc. | Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I |
| EP2365001A3 (en) * | 2003-05-01 | 2012-03-28 | Imclone LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| US7579157B2 (en) * | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
| ES2351395T3 (es) * | 2003-08-13 | 2011-02-04 | Pfizer Products Inc. | Anticuerpos humanos modificados anti-igf-1r. |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| KR20080019249A (ko) * | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
| AU2007229554A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-IGF-1R human monoclonal antibody formulation |
-
2008
- 2008-03-20 MX MX2009010179A patent/MX2009010179A/es not_active Application Discontinuation
- 2008-03-20 UA UAA200909552A patent/UA96473C2/ru unknown
- 2008-03-20 US US12/528,882 patent/US20100260766A1/en not_active Abandoned
- 2008-03-20 JP JP2009554753A patent/JP2010522208A/ja active Pending
- 2008-03-20 EA EA200970880A patent/EA200970880A1/ru unknown
- 2008-03-20 WO PCT/US2008/057718 patent/WO2008116103A2/en not_active Ceased
- 2008-03-20 CN CN200880009446A patent/CN101668540A/zh active Pending
- 2008-03-20 CA CA002681743A patent/CA2681743A1/en not_active Abandoned
- 2008-03-20 BR BRPI0809112-9A patent/BRPI0809112A2/pt not_active IP Right Cessation
- 2008-03-20 KR KR1020097019642A patent/KR20090113340A/ko not_active Abandoned
- 2008-03-20 AU AU2008228823A patent/AU2008228823A1/en not_active Abandoned
- 2008-03-20 EP EP08744136A patent/EP2136839A4/en not_active Withdrawn
-
2009
- 2009-08-10 IL IL200321A patent/IL200321A0/en unknown
- 2009-08-13 ZA ZA200905636A patent/ZA200905636B/xx unknown
- 2009-08-28 CR CR11005A patent/CR11005A/es not_active Application Discontinuation
- 2009-09-18 DO DO2009000222A patent/DOP2009000222A/es unknown
- 2009-09-18 TN TNP2009000382A patent/TN2009000382A1/fr unknown
- 2009-09-21 EC EC2009009642A patent/ECSP099642A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522208A5 (OSRAM) | ||
| JP2010529999A5 (OSRAM) | ||
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| JP2007262090A5 (OSRAM) | ||
| NZ595526A (en) | Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant | |
| JP2016513069A5 (OSRAM) | ||
| UA96473C2 (ru) | Жидкая стойкая композиция, которая содержит антитело imc-а12 | |
| JP2006517944A5 (OSRAM) | ||
| UA107557C2 (xx) | Композиція антитіла офатумумабу | |
| JP2013527189A5 (OSRAM) | ||
| JP2007522094A5 (OSRAM) | ||
| WO2009048148A1 (ja) | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 | |
| JP2012515184A5 (OSRAM) | ||
| HRP20161577T1 (hr) | Inhibitori replikacije virusa gripe | |
| JP2014520852A5 (OSRAM) | ||
| JP2008531742A5 (OSRAM) | ||
| JP2005527551A5 (OSRAM) | ||
| CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
| JP2011111444A5 (OSRAM) | ||
| JP2011068692A5 (OSRAM) | ||
| JP2009523791A5 (OSRAM) | ||
| EP1976554A4 (en) | DE-N-ACETYL-SIALIC ACID ANTIGENES, ANTIBODIES, AND METHOD FOR USE IN CANCER THERAPY | |
| RU2010104395A (ru) | Пероральные фармацевтические растворы, содержащие телбивудин | |
| JP2010540461A5 (OSRAM) | ||
| JP2006342148A5 (OSRAM) |